A state-of-art facility for a company that's committed to research
MSD Biotech, Dublin began construction in 2018 and has progressed at an impressive rate since then. The site plays a pivotal role in the manufacture of MSD’s biologics-based medicines, including immuno-oncology, and it has expanded MSD’s current internal network of biologics drug substance manufacturing plants since full manufacturing operations began in 2021.